J Breast Cancer.  2019 Mar;22(1):86-95. 10.4048/jbc.2019.22.e14.

Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients

Affiliations
  • 1Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea.
  • 2Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jjjongwr@hanmail.net
  • 3Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
  • 4Clinical Research Center, Asan Medical Center, Seoul, Korea.

Abstract

PURPOSE
Discontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication adherence by using prescription data extracted from patient electronic medical records.
METHODS
A total of 5,928 patients diagnosed with invasive, non-metastatic breast cancer, who underwent surgery from January 1, 1997 to December 31, 2009, were enrolled retrospectively. The prescription data for 4.5 years of hormonal treatment and breast cancer-related events after treatment completion were analyzed. We examined the characteristics and prognoses of breast cancer in patients with and without a 4-week gap.
RESULTS
Patients with a gap showed a significantly higher risk of breast cancer recurrence, distant metastasis, breast cancer-specific death, and overall death after adjustment (hazard ratio [HR], 1.389; 95% confidence interval [CI], 1.089-1.772; HR, 1.568; 95% CI, 1.158-2.123; HR, 2.108; 95% CI, 1.298-3.423; and HR, 2.102; 95% CI, 1.456-3.034, respectively). When patients were categorized based on gap summation, the lower third (160 days) and fourth (391 days) quartiles showed a significantly higher risk of distant metastasis (HR, 1.758; 95% CI, 1.186-2.606 and HR, 1.844; 95% CI, 1.262-2.693, respectively).
CONCLUSION
A gap of > 4 weeks in hormonal treatment has negative effects on breast cancer prognosis, and can hence be used as a sentinel index of higher risk due to treatment non-adherence. Further evaluation is needed to determine whether the gap can be used as a universal index for monitoring the adherence to hormonal treatment.

Keyword

Breast Neoplasms; Estrogen Antagonists; Medication Adherence; Neoplasm Metastasis

MeSH Terms

Breast Neoplasms*
Breast*
Electronic Health Records*
Estrogen Antagonists
Humans
Medication Adherence
Neoplasm Metastasis
Prescriptions*
Prognosis
Recurrence
Retrospective Studies
Estrogen Antagonists

Figure

  • Figure 1 Flow diagram of patient selection; a total of 5,928 patients were enrolled in this study. AMC = Asan Medical Center.

  • Figure 2 Unadjusted Kaplan-Meier curves comparing patients with a gap and patients without a gap in terms of 4 possible outcomes of breast cancer: (A) Breast cancer recurrence (of any type), (B) Distant metastasis, (C) Breast cancer-specific death, and (D) Overall death.

  • Figure 3 RR of the gap sum for distant metastasis of breast cancer, adjusted by age at diagnosis, breast cancer stage, chemotherapy, and radiation therapy. RR = relative risk.


Reference

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687–1717.
2. Aebi S, Davidson T, Gruber G, Cardoso F. ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22:Suppl 6. vi12–vi24.
Article
3. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32:2255–2269.
Article
4. Park BW, Park HS. Adjuvant hormonal therapy: current standard and practical issues. J Breast Cancer. 2010; 13:242.
Article
5. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31:5.
Article
6. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381:805–816.
7. Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, et al. A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. BMJ Open. 2014; 4:e005285.
Article
8. Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014; 7:378–387.
Article
9. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat. 2013; 138:185–191.
Article
10. He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K. Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol. 2015; 33:2262–2269.
Article
11. Bradley CJ, Dahman B, Jagsi R, Katz S, Hawley S. Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat. 2015; 154:417–422.
Article
12. Cho J, Jung SY, Lee JE, Shim EJ, Kim NH, Kim Z, et al. A review of breast cancer survivorship issues from survivors' perspectives. J Breast Cancer. 2014; 17:189–199.
Article
13. Hershman DL, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016; 157:133–143.
Article
14. Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, et al. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol. 2014; 32:2318–2327.
Article
15. Van Liew JR, Christensen AJ, de Moor JS. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv. 2014; 8:521–531.
Article
16. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126:529–537.
Article
17. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013; 109:1172–1180.
Article
18. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99:1763–1768.
Article
19. Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, Alone and in Sequence. J Clin Oncol. 2016; 34:2452–2459.
Article
20. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134:459–478.
Article
21. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014; 67:267–277.
Article
22. Fairman KA, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manag Care Spec Pharm. 2000; 6:499–506.
Article
23. Shin SY, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, et al. A de-identification method for bilingual clinical texts of various note types. J Korean Med Sci. 2015; 30:7–15.
Article
24. Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016; 25:953–959.
Article
25. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013; 108:1515–1524.
Article
26. Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008; 206:66–75.
Article
27. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009; 117:91–98.
Article
28. Ayres LR, Baldoni AO, Borges AP, Pereira LR. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm. 2014; 36:45–54.
Article
29. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol. 2007; 25:2360–2368.
Article
30. Wuensch P, Hahne A, Haidinger R, Meißler K, Tenter B, Stoll C, et al. Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol. 2015; 141:55–60.
Article
Full Text Links
  • JBC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr